Last reviewed · How we verify
An Open-label, Phase II Clinical Trial of of a Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Adverse Reactions Nausea of Niraparib in in the First-line Maintenance Treatment in Advanced Epithelial Ovarian Cancer (EOC) Patients
This study is an open-label, single-Arm， phase II clinical trial of a Chinese Patent Medicine Yangzheng Xiaoji Capsule to improve the adverse reaction nausea of Niraparib in the first-line maintenance treatment in advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
Details
| Lead sponsor | Sichuan Cancer Hospital and Research Institute |
|---|---|
| Phase | Phase 2 |
| Status | UNKNOWN |
| Enrolment | 50 |
| Start date | 2022-12 |
| Completion | 2025-05 |
Conditions
- Ovarian Cancer
Interventions
- Yangzheng Xiaoji
- Niraparib
Primary outcomes
- Incidence of nausea — 3 cycles (each cycle is 28 days)
all grade of nausea base on CTCAE V5.0
Countries
China